ADMA BIOLOGICS, INC.

Item 1.

Legal Proceedings.

On July 10, 2026, plaintiff Lisa Mazzarino filed a putative securities class action lawsuit, Mazzarino v. ADMA Biologics, Inc. et al., Case No. 2:26-cv-06918 (D.N.J.), against the Company, Adam Grossman, our director, President and Chief Executive Officer, Jerrold Grossman, our Vice Chairman of the Board, and Brad Tade, our former Chief Financial Officer and Treasurer, in the United States District Court for the District of New Jersey (the “Securities Class Action”). The complaint alleges violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, as amended, and Rule 10b-5 promulgated thereunder. The action seeks monetary damages in an unspecified amount. On October 16, 2026, the Court appointed Seafarers Health and Benefits Plan and Seafarers Vacation Plan as the lead plaintiff and further ordered all securities class actions arising out of the same or substantially similar subject matter to be consolidated into the Securities Class Action. The parties plan to present a proposed schedule to the Court for an amended complaint and the defendants’ anticipated motion to dismiss. The litigation remains at a preliminary stage. We believe that the claims asserted in the lawsuit are without merit and intend to vigorously defend against the action. At this time, we are unable to predict the outcome of the litigation or reasonably estimate the amount or range of any potential loss, if any, that may result from the matter.

Three stockholder derivative actions alleging substantially the same facts as the Securities Class Action have been filed to date: (1)Zunya v. Elms, et al., Case No. 2:26-cv-10811-ES-AME (D.N.J.) (the “Zunya Action”), filed on August 24, 2026; (2)Parris v. Elms, et al., Case No. 2:26-cv-11014-ES-AME (D.N.J.) (the “Parris Action”), filed on August 26, 2026; and (3)ES Trust v. Grossman, et al., Case No. 2:26-cv-11361-ES-AME (D.N.J.) (the “ES Trust Action,” and, collectively with the Zunya Action and Parris Action, the “Derivative Actions”), filed on September 2, 2026. The Derivative Actions were filed in the United States District Court for the District of New Jersey. The plaintiffs in the Derivative Actions purport to assert claims on the Company’s behalf against certain of the Company’s current and former executives and members of our Board for breach of fiduciary duty, aiding and abetting breach of fiduciary duty, corporate waste, unjust enrichment, and violations of the Securities Exchange Act of 1934, as amended. The Derivative Actions seek unspecified monetary and punitive damages, disgorgement of profits from the named defendants, an award of costs and expenses, including reasonable attorneys’ fees, and corporate governance reforms. On September 21, 2026, the Court consolidated the Derivative Actions with the new caption In re Adma Biologics, Inc. Stockholder Derivative Litigation, Lead Case No. 2:26-cv-10811-ES-AME. We intend to move for a stay of the Derivative Actions pending resolution of the Securities Class Action.

We also received three demands to inspect books and records pursuant to Section 220 of the Delaware General Corporation Law seeking documents related to the facts alleged in the Securities Class Action (the “Section 220 Demands”). We responded to each of the Section 220 Demands and continue to discuss those responses with the requesting stockholders. The stockholders who served the Section 220 Demands may file additional Derivative Actions.